How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Description:
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals Clarity Clinical Trials Contactclinicaltrials@claritypharmaceuticals.com
+61 (0) 2 9209 4037
Government Study Link:
NCT06970847 - Click here to see study onClinicalTrials.gov
64Cu-SAR-bisPSMA
Isotope(s):
Target(s):
- PSMA
Ligand: Small Molecules
Chelator: SAR
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
🇺🇸 United States
XCancer - Omaha
17607 Gold Plaza, Omaha, Nebraska 68130, United States
Principal Investigator
Luke T. Nordquist, MD
The Urology Place
San Antonio, Texas, United States
Principal Investigator
Naveen Kella, MD
Biogenix Molecular LLC
Miami, Florida 33165, United States
Principal Investigator
Frankis Almaguel, MD
